



ACC.09
58th Annual Scientific Session
MARCH 29 - 31 • ORLANDO

i2 summit 2009
innovation in intervention
ACC in partnership with CRF




NAPLES II

Novel Approaches for Preventing or Limiting Event Study

Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction

Carlo Briguori, MD, PhD
Laboratory of Interventional Cardiology
Clinica Mediterranea, Naples - Italy



Disclosure Statement of Financial Interest

I, Carlo Briguori DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation.

This is the **Bulleted List** slide.

To create this particular slide, click the **NEW SLIDE** button on your toolbar and choose the **BULLETED LIST** format. (Top row, second from left)

The **Sub-Heading** and **footnote** will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a **Sub-Heading**, let us know when you hand in your presentation for clean-up and we'll adjust where the bullets begin on your master page.

Also, be sure to insert the presentation title onto the **BULLETED LIST MASTER** as follows:

1. Choose **View / Master / Slide Master** from your menu.
2. Select the text at the bottom of the slide and type in a short version of your presentation title.
3. Click the **SLIDE VIEW** button in the lower left hand part of your screen to return to the slide show. (Small white rectangle)



Background



- Periprocedural non-Q MI is a frequent and prognostically important complication of PCI¹.
- The available data suggest that statin prevent periprocedural MI²⁻³
- Statin administration should be started at least 3 - 7 days before the procedure²
- It is unknown whether a single, high (80 mg) loading (within 24 hours) dose of atorvastatin may reduce the rate of periprocedural MI.

¹ Hermann J. *Eur Heart J* 2005; 25: 2493

² Pasceri V. et al. . *Circulation* 2004;110:674-8

³ Briguori C et al. *Eur Heart J* 2004;25:1822-8

This is the **Bulleted List** slide.


To create this particular slide, click the **NEW SLIDE** button on your toolbar and choose the **BULLETED LIST** format. (Top row, second from left)

The **Sub-Heading** and **footnote** will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a **Sub-Heading**, let us know when you hand in your presentation for clean-up and we'll adjust where the bullets begin on your master page.

Also, be sure to insert the presentation title onto the **BULLETED LIST MASTER** as follows:

1. Choose **View / Master / Slide Master** from your menu.
2. Select the text at the bottom of the slide and type in a short version of your presentation title.
3. Click the **SLIDE VIEW** button in the lower left hand part of your screen to return to the slide show. (Small white rectangle)

Pleiotropic effects





Background



- An immediate significant effect of just a single dose of statin has been previously reported
 - Ostadal et al. demonstrated that a single dose of cerivastatin at the time of admission of patients with unstable angina or non-ST elevation MI positively influences the inflammatory parameters CRP and interleukin-6 at 24 hours (*Mol Cell Biochem* 2003;246:45-50)
 - Romano et al. described that a 24-h treatment with lovastatin and simvastatin induces inhibition of monocyte chemotactic protein-1 (MCP-1) synthesis in mononuclear and endothelial cells in vitro (*Lab Invest* 2000;80:1095-1100)
 - Statins indeed have beneficial effects on endothelial function by a rapid increase in nitric oxide bioavailability; this effect has been observed as early as 3 hours following statin administration (Laufs et al. *Circulation* 1998;97:1129-1135)


This is the **Bulleted List** slide.

To create this particular slide, click the **NEW SLIDE** button on your toolbar and choose the **BULLETED LIST** format. (Top row, second from left)

The **Sub-Heading** and **footnote** will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a **Sub-Heading**, let us know when you hand in your presentation for clean-up and we'll adjust where the bullets begin on your master page.

Also, be sure to insert the presentation title onto the **BULLETED LIST MASTER** as follows:

1. Choose **View / Master / Slide Master** from your menu.
2. Select the text at the bottom of the slide and type in a short version of your presentation title.
3. Click the **SLIDE VIEW** button in the lower left hand part of your screen to return to the slide show. (Small white rectangle)



Purpose

- To assess whether a single, high (80 mg), loading (within 24 hours) dose of atorvastatin is effective in preventing elevation of biomarkers of MI following elective coronary stent implantation.

This is the **Bulleted List** slide.

To create this particular slide, click the **NEW SLIDE** button on your toolbar and choose the **BULLETED LIST** format. (Top row, second from left)

The **Sub-Heading** and **footnote** will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a **Sub-Heading**, let us know when you hand in your presentation for clean-up and we'll adjust where the bullets begin on your master page.

Also, be sure to insert the presentation title onto the **BULLETED LIST MASTER** as follows:

1. Choose **View / Master / Slide Master** from your menu.
2. Select the text at the bottom of the slide and type in a short version of your presentation title.
3. Click the **SLIDE VIEW** button in the lower left hand part of your screen to return to the slide show. (Small white rectangle)

NAPLES II

- **DESIGN:** Prospective, randomized, double-arm, 2-center clinical, spontaneous study

Elective PCI in de novo lesions, in native coronary artery

No statin therapy
Biomarker negative

ASA
Clopidogrel
(loading dose 300 mg
the day before procedure)


Atorvastatin 80 mg

No atorvastatin


Elective PCI

CKMB >3X ULN





Sample size



- **Hypothesis:**
 - Reduction in the primary endpoint from 15% in the *Control* group to 8% in the *Atorvastatin* group¹⁻²
- **Sample size:**
 - A total of 650 patients (325 each group) will be necessary to give the study 80% power and a significance level <0.05

¹ Pasceri V, et al. . *Circulation* 2004;110:674-8
² Briguori C et al. *Eur Heart J* 2004;25:1822-8

This is the **Bulleted List** slide.

To create this particular slide, click the **NEW SLIDE** button on your toolbar and choose the **BULLETED LIST** format. (Top row, second from left)

The **Sub-Heading** and **footnote** will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a **Sub-Heading**, let us know when you hand in your presentation for clean-up and we'll adjust where the bullets begin on your master page.

Also, be sure to insert the presentation title onto the **BULLETED LIST MASTER** as follows:

1. Choose **View / Master / Slide Master** from your menu.
2. Select the text at the bottom of the slide and type in a short version of your presentation title.
3. Click the **SLIDE VIEW** button in the lower left hand part of your screen to return to the slide show. (Small white rectangle)



Inclusion criteria




- Age ≥ 18 y
- *De novo* lesion in a native coronary artery
- Elective PCI
- Normal cardiac biomarkers
- No statin therapy




Exclusion criteria



- Primary or rescue PCI
- ACS with elevated cardiac markers
- Pregnancy
- Restenotic lesion
- SVG or LIMA treatment
- Active statin therapy
- History of intolerance to statin



Definitions



- **Non-Q wave MI:**
 - CKMB $\geq 3X$ ULN
- **Q wave MI:**
 - CKMB $\geq 2X$ ULN with new significant Q waves in ≥ 2 contiguous leads

Thygesen K et al. *Eur Heart J* 2007;28:2525-38.8


This is the **Bulleted List** slide.

To create this particular slide, click the **NEW SLIDE** button on your toolbar and choose the **BULLETED LIST** format. (Top row, second from left)

The **Sub-Heading** and **footnote** will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a **Sub-Heading**, let us know when you hand in your presentation for clean-up and we'll adjust where the bullets begin on your master page.

Also, be sure to insert the presentation title onto the **BULLETED LIST MASTER** as follows:

1. Choose **View / Master / Slide Master** from your menu.
2. Select the text at the bottom of the slide and type in a short version of your presentation title.
3. Click the **SLIDE VIEW** button in the lower left hand part of your screen to return to the slide show. (Small white rectangle)





Clinical Characteristics



	Atorvastatin Group (N=338)	Control Group (N=330)
Age, yrs (mean \pm SD)	64 \pm 9	65 \pm 10
Male, %	266 (78.7%)	263 (79.7%)
BMI (kg/m ²)	27.8 \pm 3.8	27.4 \pm 3.5
Symptoms		
Asymptomatic	45 (13.3%)	34 (10.3%)
Stable angina	285 (84.3%)	288 (87.3%)
Family history for CAD	101 (30%)	112 (34%)
Diabetes mellitus	130 (38.6%)	121 (36.8%)
Hypertension, %	131 (78%)	125 (74.9%)
Current smoker, %	79 (24%)	66 (20%)
Prior MI, %	113 (33.4%)	97 (29.4%)
Prior PCI*, %	41 (12.1%)	31 (9.4%)
Prior CABG, %	24 (7.1%)	27 (8.1%)
LVEF, % (mean \pm SD)	55.7 \pm 9.5	55.5 \pm 9.9
β -blockers	130 (38.5%)	129 (39.1%)

* Percutaneous intervention performed in a different vessel and/or lesion.




Biochemical Characteristics

	Atorvastatin Group (N=338)	Control Group (N=330)
Serum creatinine, median (IQR)	1.16 (1.00-1.32)	1.18 (1.00-1.35)
GFR (ml/min/1.73 m ²)	65 ± 17	64 ± 19
Fibrinogen, mg/dL	124 (36.6%)	140 (42.4%)
Lipid, mg/dL	379 ± 123	363 ± 100
Total Cholesterol		
LDL-C	211 ± 46	210 ± 42
HDL-C	126 ± 35	129 ± 37



Rate of high CRP





Angiographic & Procedural Characteristics



	Atorvastatin Group (N=338)	Control Group (N=330)
Distribution of CAD		
1-vessel	128 (37.9%)	125 (37.9%)
2-vessel	121 (35.8%)	117 (35.5%)
3-vessel	89 (26.3%)	88 (26.6%)
Target vessel	371	366
LAD	186 (50.1%)	185 (50.5%)
Cx	72 (19.5%)	71 (19.4%)
RCA	107 (28.8%)	105 (28.5%)
LM	6 (1.6%)	6 (1.6%)
Lesion site	436	426
Ostial	46 (10.7%)	47 (11%)
Proximal	193 (44.2%)	189 (44.4%)
Mid	161 (36.9%)	172 (40.4%)
Distal	35 (8.2%)	18 (4.2%)



Angiographic & Procedural Characteristics



	Atorvastatin Group (N=338)	Control Group (N=330)
Multivessel stenting	37 (11%)	33 (10%)
Direct stenting	96 (28.5%)	100 (30.3%)
Atherectomy	5 (1.5%)	7 (2.1%)
No. treated vessel/patient	1.1 ± 0.5	1.1 ± 0.3
No. treated lesion/patient	1.3 ± 0.6	1.3 ± 0.6
CTO	64 (18.9%)	59 (17.9%)
Thrombus	6 (1.7%)	9 (2.7%)
Complex (B2/C) lesions	173 (51.3%)	177 (53.7%)
Bifurcation lesions	56 (16.7%)	55 (16.6%)
GP IIb/IIIa inhibitors	43 (12.7%)	46 (13.6%)
Calcified lesions	80 (23.7%)	88 (26.8%)

Angiographic & Procedural Characteristics



	Atorvastatin Group (N=338)	Control Group (N=330)
Preprocedural QCA		
RVD, mm	3.16 ± 0.62	3.23 ± 0.59
MLD, mm	0.51 ± 0.44	0.51 ± 0.40
DS, %	85 ± 12	84 ± 13
Lesion length, mm	19 ± 8	19 ± 8
Postprocedural QCA		
RVD, mm	3.36 ± 0.61	3.41 ± 0.58
MLD, mm	3.34 ± 0.61	3.37 ± 0.60
DS, %	2 ± 3	2 ± 3
Stent length, mm	30 ± 16	30 ± 16
Max inflation pressure, atm	15 ± 4	15 ± 4
TIMI flow grade pre		
0/1	54 (16%)	54 (16.5%)
2/3	284 (84%)	276 (83.5%)
TIMI flow grade post		
0/1	1 (0.3%)	0
2/3	337 (99.7%)	330 (100%)
BA ratio	1.05 ± 0.12	1.03 ± 0.09




Angiographic Complications

	Atorvastatin Group (N=338)	Control Group (N=330)	P
Major dissection	1 (0.59%)	3 (0.90%)	0.68
Abrupt closure	1 (0.29%)	0	0.48
Slow/No reflow	2 (0.59%)	8 (2.40%)	0.06
Thrombus formation	2 (0.59%)	0	0.50
Side branch closure/	5 (1.48%)	7 (2.12%)	0.57
Distal embolization	2 (0.59%)	2 (0.60%)	1.00
Perforation	2 (0.59%)	2 (0.60%)	1.00
Any of the above	16 (4.7%)	22 (6.6%)	0.31




CKMB >3X ULN



■ Atorvastatin group (n= 338)
■ Control group (n = 330)




cTnl >3X ULN






CKMB \geq 3X ULN & CRP





Tnl \geq 3X ULN & CRP





In-hospital outcome



	Atorvastatin Group (N=338)	Control Group (N=330)	P value
Death	1 (0.3%)	0	NS
MI	33 (9.8%)	52 (15.8%)	0.014
Q-wave MI	1 (0.3%)	0	NS
Non Q-wave MI	32 (9.5%)	52 (15.8%)	0.014
Unplanned revasc	0	0	-
Stent thrombosis	2 (0.58%)	1 (0.30%)	0.57
Composite	34 (10%)	52 (15.7%)	0.029



Conclusions

- A single, high (80 mg) loading (within 24 hours) dose of atorvastatin reduces the incidence of periprocedural non Q wave MI in elective PCI.
- This cardioprotective effect seems to be more pronounced in patients with high CRP level at baseline



Naples II trial group



- Clinica Mediterranea, Naples
- Cath Lab group:
 - C. Briguori
 - A. Focaccio
 - G. Visconti
- ICU group:
 - B. Ricciardelli
 - B. Golia
 - M.T. Librera



Naples II trial group



- San Raffaele Hospital, Milan
- Cath Lab group:
 - A. Colombo
 - M. Montorfano
 - A. Chieffo
- ICU group:
 - A. Castelli
 - M. Mongiardo
 - Study coordinator
 - A. Ferrari